Pregnancy and cancer—a rare but emotionally charged combination that leaves expectant mothers and their healthcare providers navigating a complex web of decisions. But here's the stark reality: only about one in 1,000 to 2,000 pregnancies involves a new cancer diagnosis, yet the implications are profound, affecting both the mother's well-being and the fetus's health. The American Society of Clinical Oncology (ASCO) has stepped in with a groundbreaking guideline, published in the Journal of Clinical Oncology, to shed light on this delicate balance. And this is the part most people miss: it’s not just about treating cancer; it’s about honoring the mother’s wishes, understanding the risks, and making informed choices that consider both lives at stake.
Dr. Mikkael A. Sekeres, a leading hematologist at Sylvester Comprehensive Cancer Center, emphasizes the rarity of this scenario but highlights its deep medical and psychosocial impact. He explains, ‘As we engage in shared decision-making, we must weigh the cancer’s aggressiveness, the toxicity of diagnostic procedures, and the patient’s goals.’ But here's where it gets controversial: how do we balance the mother’s desire to continue her pregnancy with the potential risks of cancer treatment to the fetus?
The ASCO guideline tackles these questions head-on, offering evidence-based recommendations on diagnostics, treatment, and obstetrical care. However, the evidence itself is largely based on retrospective studies, case series, and individual reports—a limitation that raises eyebrows. Is this enough to guide such critical decisions? The authors argue that while the evidence quality is low, the recommendations are strong, providing ‘real-world data’ to inform clinical practice. But does this data truly suffice for such high-stakes scenarios?
Dr. Ann H. Partridge, a pioneer in young adult cancer care at Dana-Farber Cancer Institute, stresses three key considerations: understanding the patient’s preferences about continuing the pregnancy, weighing the risks of the disease and treatment, and evaluating the risks to the fetus—both from treatment and from the cancer itself. She adds, ‘We must be honest about what we know and don’t know, both from a data perspective and for the individual patient.’ But what happens when the data is unclear, and the risks are high? Who bears the burden of that uncertainty?
The guideline recommends a multidisciplinary approach, involving pharmacists and other specialists to tailor treatment plans. It also prioritizes patient autonomy, though it acknowledges that emergencies may require immediate therapy—even if it means terminating the pregnancy. Is this a fair trade-off? And how do we ensure the mother’s voice remains central in these decisions?
One of the most contentious issues is the use of drugs with unknown teratogenic potential. Dr. Sekeres notes that pregnant patients are often excluded from clinical trials, leaving clinicians with limited data. ‘We often delay therapy or turn to alternatives with minimal data,’ he explains. Dr. Partridge echoes this concern, stating that the risks of newer therapies like bispecific agents or antibody-drug conjugates are ‘not well understood at all.’ Should we prioritize the mother’s health, even if it means exposing the fetus to unknown risks? Or should we err on the side of caution, potentially compromising the mother’s treatment?
These questions don’t have easy answers, but they demand discussion. The ASCO guideline is a vital step forward, but it also opens the door to debate. What do you think? Should patient autonomy always come first, or are there situations where the fetus’s health must take precedence? Share your thoughts in the comments—let’s spark a conversation that could shape the future of cancer care during pregnancy.
